NA 放射線治療市場 - 2030年までの産業動向と予測NA Radiotherapy Market - Industry Trends and Forecast to 2030 北米の放射線治療市場は2023年から2030年の予測期間でCAGR 8.6%を記録すると予測されている。この新しい市場レポートは、歴史的年2021年のデータを含み、計算基準年は2022年、予測期間は2023年から2030年です。 ... もっと見る
日本語のページは自動翻訳を利用し作成しています。
サマリー北米の放射線治療市場は2023年から2030年の予測期間でCAGR 8.6%を記録すると予測されている。この新しい市場レポートは、歴史的年2021年のデータを含み、計算基準年は2022年、予測期間は2023年から2030年です。市場区分 北米の放射線治療市場:製品・サービス別(サービス、製品、ソフトウェア)、タイプ別(外部ビーム放射線治療、内部放射線治療、全身放射線治療/放射性医薬品、その他)、用途別(乳がん、肺がん、前立腺がん、大腸がん、用途(乳がん、肺がん、前立腺がん、大腸がん、リンパ腫、肝がん、甲状腺がん、脳腫瘍、子宮頸がん、脊椎がん、その他)、エンドユーザー(病院、放射線治療センター、専門クリニック、その他)、流通チャネル(直接取引業者、第三者流通業者、その他)、国(U.S.,産業動向と2030年までの予測 北米放射線治療市場ダイナミクスの概要 促進要因 - がん有病率の増加 抑制要因 - 熟練した認定専門家の不足 機会 - がん治療にかかる医療費の増加 市場プレイヤー 北米の放射線治療市場で事業を展開する主な市場プレーヤーを以下に挙げる: - ビューレイ・テクノロジー社(ビューレイの子会社) - シーメンスヘルスケアGmbH - エレクタAB - アキュレイ・インコーポレイテッド - IBAワールドワイド - Eckert & Ziegler BEBIG - ブレインラボAG - Koninklijke Philips N.V. - GEヘルスケア - 日立製作所 目次TABLE OF CONTENTS1 INTRODUCTION 36 1.1 OBJECTIVES OF THE STUDY 36 1.2 MARKET DEFINITION 36 1.3 OVERVIEW OF THE NORTH AMERICA RADIOTHERAPY MARKET 36 1.4 CURRENCY AND PRICING 38 1.5 LIMITATIONS 38 1.6 MARKETS COVERED 38 2 MARKET SEGMENTATION 41 2.1 MARKETS COVERED 41 2.2 GEOGRAPHICAL SCOPE 42 2.3 YEARS CONSIDERED FOR THE STUDY 43 2.4 DBMR TRIPOD DATA VALIDATION MODEL 44 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 47 2.6 MULTIVARIATE MODELLING 48 2.7 PRODUCT AND SERVICES SEGMENT LIFELINE CURVE 49 2.8 MARKET END USERS COVERAGE GRID 50 2.9 DBMR MARKET POSITION GRID 51 2.10 VENDOR SHARE ANALYSIS 52 2.11 SECONDARY SOURCES 53 2.12 ASSUMPTIONS 53 3 EXECUTIVE SUMMARY 54 4 PREMIUM INSIGHTS 56 4.1 PESTLE ANALYSIS 57 4.2 PORTER'S FIVE FORCES MODEL 58 4.3 PRICING ANALYSIS 59 5 REGULATORY GUIDELINES FOR RADIOTHERAPY 61 6 MARKET OVERVIEW 64 6.1 DRIVERS 66 6.1.1 GROWING PREVALENCE OF CANCER DISEASE 66 6.1.2 NOVEL TECHNOLOGY IN RADIOTHERAPY FOR CANCER TREATMENT 66 6.1.3 INCREASING ADOPTION OF RADIOTHERAPY DEVICES AND PROCEDURES 67 6.1.4 RISING PREFERENCE FOR NON-SURGICAL PROCEDURES 67 6.2 RESTRAINTS 67 6.2.1 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 67 6.2.2 HIGH COST OF TREATMENT AND RADIOTHERAPY PROCEDURE 68 6.3 OPPORTUNITIES 68 6.3.1 INCREASING HEALTHCARE EXPENDITURE FOR CANCER TREATMENT 68 6.3.2 GROWING GOVERNMENT INITIATIVES TOWARD CANCER TREATMENT 69 6.3.3 RISING PATIENTS AWARENESS TOWARDS CANCER TREATMENT 70 6.4 CHALLENGES 70 6.4.1 STRICT REGULATIONS AND STANDARDS FOR APPROVAL AND COMMERCIALIZATION OF RADIOTHERAPY PRODUCTS 70 6.4.2 RISK OF RADIATION EXPOSURE 71 7 NORTH AMERICA RADIOTHERAPY MARKET, BY PRODUCT & SERVICES 72 7.1 OVERVIEW 73 7.2 SERVICES 75 7.3 PRODUCT 75 7.4 SOFTWARE 75 8 NORTH AMERICA RADIOTHERAPY MARKET, BY TYPE 76 8.1 OVERVIEW 77 8.2 EXTERNAL-BEAM RADIATION THERAPY 79 8.3 INTERNAL RADIATION THERAPY 79 8.4 SYSTEMIC RADIOTHERAPY/ RADIOPHARMACEUTICALS 79 8.5 OTHERS 79 9 NORTH AMERICA RADIOTHERAPY MARKET, BY APPLICATION 80 3.1 OVERVIEW 81 9.1 BREAST CANCER 84 9.2 LUNG CANCER 84 9.3 PROSTATE CANCER 84 9.4 COLORECTAL CANCER 84 9.5 LYMPHOMA 84 9.6 LIVER CANCER 84 9.7 THYROID CANCER 84 9.8 BRAIN CANCER 84 9.9 CERVICAL CANCER 85 9.10 SPINE CANCER 85 9.11 OTHERS 85 10 NORTH AMERICA RADIOTHERAPY MARKET, BY END USER 86 10.1 OVERVIEW 87 10.2 HOSPITALS 89 10.3 RADIATION THERAPY CENTERS 89 10.4 SPECIALTY CLINICS 89 10.5 OTHERS 89 11 NORTH AMERICA RADIOTHERAPY MARKET, BY DISTRIBUTION CHANNEL 90 11.1 OVERVIEW 91 11.2 DIRECT TENDERS 93 11.3 THIRD PARTY DISTRIBUTORS 93 11.4 OTHERS 93 12 NORTH AMERICA RADIOTHERAPY MARKET, BY REGION 94 12.1 NORTH AMERICA 95 13 NORTH AMERICA RADIOTHERAPY MARKET: COMPANY LANDSCAPE 116 13.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 116 14 SWOT ANALYSIS 117 15 COMPANY PROFILE 118 15.1 SIEMENS HEALTHCARE GMBH 118 15.1.1 COMPANY SNAPSHOT 118 15.1.2 REVENUE ANALYSIS 118 15.1.3 COMPANY SHARE ANALYSIS 119 15.1.4 PRODUCT PORTFOLIO 119 15.1.5 RECENT DEVELOPMENT 119 15.2 ELEKTA 120 15.2.1 COMPANY SNAPSHOT 120 15.2.2 REVENUE ANALYSIS 120 15.2.3 COMPANY SHARE ANALYSIS 121 15.2.4 PRODUCT PORTFOLIO 121 15.2.5 RECENT DEVELOPMENTS 121 15.3 GENERAL ELECTRIC COMPANY 122 15.3.1 COMPANY SNAPSHOT 122 15.3.2 REVENUE ANALYSIS 122 15.3.3 COMPANY SHARE ANALYSIS 123 15.3.4 PRODUCT PORTFOLIO 123 15.3.5 RECENT DEVELOPMENT 123 15.4 HITACHI, LTD. 124 15.4.1 COMPANY SNAPSHOT 124 15.4.2 REVENUE ANALYSIS 124 15.4.3 PRODUCT PORTFOLIO 125 15.4.4 RECENT DEVELOPMENT 125 15.5 KONINKLIJKE PHILIPS N.V. 126 15.5.1 COMPANY SNAPSHOT 126 15.5.2 REVENUE ANALYSIS 126 15.5.3 COMPANY SHARE ANALYSIS 127 15.5.4 PRODUCT PORTFOLIO 127 15.5.5 RECENT DEVELOPMENT 127 15.6 ACCURACY INCORPORATED 128 15.6.1 COMPANY SNAPSHOT 128 15.6.2 REVENUE ANALYSIS 128 15.6.3 PRODUCT PORTFOLIO 129 15.6.4 RECENT DEVELOPMENT 129 15.7 BEBIG MEDICAL. 130 15.7.1 COMPANY SNAPSHOT 130 15.7.2 PRODUCT PORTFOLIO 130 15.7.3 RECENT DEVELOPMENT 130 15.8 BRAINLAB AG 131 15.8.1 COMPANY SNAPSHOT 131 15.8.2 PRODUCT PORTFOLIO 131 15.8.3 RECENT DEVELOPMENTS 131 15.9 CANON MEDICAL SYSTEMS CORPORATION 132 15.9.1 COMPANY SNAPSHOT 132 15.9.2 REVENUE ANALYSIS 132 15.9.3 PRODUCT PORTFOLIO 133 15.9.4 RECENT DEVELOPMENT 133 15.10 ECKERT & ZIEGLER BEBIG 134 15.10.1 COMPANY SNAPSHOT 134 15.10.2 REVENUE ANALYSIS 134 15.10.3 PRODUCT PORTFOLIO 135 15.10.4 RECENT DEVELOPMENT 135 15.11 IBA WORLDWIDE 136 15.11.1 COMPANY SNAPSHOT 136 15.11.2 REVENUE ANALYSIS 136 15.11.3 PRODUCT PORTFOLIO 137 15.11.4 RECENT DEVELOPMENT 137 15.12 LINATECH INC 138 15.12.1 COMPANY SNAPSHOT 138 15.12.2 PRODUCT PORTFOLIO 138 15.12.3 RECENT DEVELOPMENT 138 15.13 MEVION MEDICAL SYSTEMS 139 15.13.1 COMPANY SNAPSHOT 139 15.13.2 PRODUCT PORTFOLIO 139 15.13.3 RECENT DEVELOPMENT 139 15.14 NORDION (CANADA) INC. (A SUBSIDIARY OF SOTERA HEALTH) 140 15.14.1 COMPANY SNAPSHOT 140 15.14.2 PRODUCT PORTFOLIO 140 15.14.3 RECENT DEVELOPMENT 140 15.15 P-CURE 141 15.15.1 COMPANY SNAPSHOT 141 15.15.2 PRODUCT PORTFOLIO 141 15.15.3 RECENT DEVELOPMENT 141 15.16 SHINVA MEDICAL INSTRUMENT CO., LTD. 142 15.16.1 COMPANY SNAPSHOT 142 15.16.2 PRODUCT PORTFOLIO 142 15.16.3 RECENT DEVELOPMENT 142 15.17 UNITED IMAGING HEALTHCARE CO., LTD 143 15.17.1 COMPANY SNAPSHOT 143 15.17.2 PRODUCT PORTFOLIO 143 15.17.3 RECENT DEVELOPMENT 143 15.18 VIEWRAY TECHNOLOGIES, INC. (“VIEWRAY”) 144 15.18.1 COMPANY SNAPSHOT 144 15.18.2 REVENUE ANALYSIS 144 15.18.3 PRODUCT PORTFOLIO 145 15.18.4 RECENT DEVELOPMENT 145 15.19 ZEISS INTERNATIONAL 146 15.19.1 COMPANY SNAPSHOT 146 15.19.2 REVENUE ANALYSIS 146 15.19.3 COMPANY SHARE ANALYSIS 147 15.19.4 PRODUCT PORTFOLIO 147 15.19.5 RECENT DEVELOPMENT 147 16 QUESTIONNAIRE 148 17 RELATED REPORTS 152
SummaryThe North America radiotherapy market is projected to register a CAGR of 8.6% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022 and the forecast period is 2023 to 2030. Table of ContentsTABLE OF CONTENTS1 INTRODUCTION 36 1.1 OBJECTIVES OF THE STUDY 36 1.2 MARKET DEFINITION 36 1.3 OVERVIEW OF THE NORTH AMERICA RADIOTHERAPY MARKET 36 1.4 CURRENCY AND PRICING 38 1.5 LIMITATIONS 38 1.6 MARKETS COVERED 38 2 MARKET SEGMENTATION 41 2.1 MARKETS COVERED 41 2.2 GEOGRAPHICAL SCOPE 42 2.3 YEARS CONSIDERED FOR THE STUDY 43 2.4 DBMR TRIPOD DATA VALIDATION MODEL 44 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 47 2.6 MULTIVARIATE MODELLING 48 2.7 PRODUCT AND SERVICES SEGMENT LIFELINE CURVE 49 2.8 MARKET END USERS COVERAGE GRID 50 2.9 DBMR MARKET POSITION GRID 51 2.10 VENDOR SHARE ANALYSIS 52 2.11 SECONDARY SOURCES 53 2.12 ASSUMPTIONS 53 3 EXECUTIVE SUMMARY 54 4 PREMIUM INSIGHTS 56 4.1 PESTLE ANALYSIS 57 4.2 PORTER'S FIVE FORCES MODEL 58 4.3 PRICING ANALYSIS 59 5 REGULATORY GUIDELINES FOR RADIOTHERAPY 61 6 MARKET OVERVIEW 64 6.1 DRIVERS 66 6.1.1 GROWING PREVALENCE OF CANCER DISEASE 66 6.1.2 NOVEL TECHNOLOGY IN RADIOTHERAPY FOR CANCER TREATMENT 66 6.1.3 INCREASING ADOPTION OF RADIOTHERAPY DEVICES AND PROCEDURES 67 6.1.4 RISING PREFERENCE FOR NON-SURGICAL PROCEDURES 67 6.2 RESTRAINTS 67 6.2.1 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 67 6.2.2 HIGH COST OF TREATMENT AND RADIOTHERAPY PROCEDURE 68 6.3 OPPORTUNITIES 68 6.3.1 INCREASING HEALTHCARE EXPENDITURE FOR CANCER TREATMENT 68 6.3.2 GROWING GOVERNMENT INITIATIVES TOWARD CANCER TREATMENT 69 6.3.3 RISING PATIENTS AWARENESS TOWARDS CANCER TREATMENT 70 6.4 CHALLENGES 70 6.4.1 STRICT REGULATIONS AND STANDARDS FOR APPROVAL AND COMMERCIALIZATION OF RADIOTHERAPY PRODUCTS 70 6.4.2 RISK OF RADIATION EXPOSURE 71 7 NORTH AMERICA RADIOTHERAPY MARKET, BY PRODUCT & SERVICES 72 7.1 OVERVIEW 73 7.2 SERVICES 75 7.3 PRODUCT 75 7.4 SOFTWARE 75 8 NORTH AMERICA RADIOTHERAPY MARKET, BY TYPE 76 8.1 OVERVIEW 77 8.2 EXTERNAL-BEAM RADIATION THERAPY 79 8.3 INTERNAL RADIATION THERAPY 79 8.4 SYSTEMIC RADIOTHERAPY/ RADIOPHARMACEUTICALS 79 8.5 OTHERS 79 9 NORTH AMERICA RADIOTHERAPY MARKET, BY APPLICATION 80 3.1 OVERVIEW 81 9.1 BREAST CANCER 84 9.2 LUNG CANCER 84 9.3 PROSTATE CANCER 84 9.4 COLORECTAL CANCER 84 9.5 LYMPHOMA 84 9.6 LIVER CANCER 84 9.7 THYROID CANCER 84 9.8 BRAIN CANCER 84 9.9 CERVICAL CANCER 85 9.10 SPINE CANCER 85 9.11 OTHERS 85 10 NORTH AMERICA RADIOTHERAPY MARKET, BY END USER 86 10.1 OVERVIEW 87 10.2 HOSPITALS 89 10.3 RADIATION THERAPY CENTERS 89 10.4 SPECIALTY CLINICS 89 10.5 OTHERS 89 11 NORTH AMERICA RADIOTHERAPY MARKET, BY DISTRIBUTION CHANNEL 90 11.1 OVERVIEW 91 11.2 DIRECT TENDERS 93 11.3 THIRD PARTY DISTRIBUTORS 93 11.4 OTHERS 93 12 NORTH AMERICA RADIOTHERAPY MARKET, BY REGION 94 12.1 NORTH AMERICA 95 13 NORTH AMERICA RADIOTHERAPY MARKET: COMPANY LANDSCAPE 116 13.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 116 14 SWOT ANALYSIS 117 15 COMPANY PROFILE 118 15.1 SIEMENS HEALTHCARE GMBH 118 15.1.1 COMPANY SNAPSHOT 118 15.1.2 REVENUE ANALYSIS 118 15.1.3 COMPANY SHARE ANALYSIS 119 15.1.4 PRODUCT PORTFOLIO 119 15.1.5 RECENT DEVELOPMENT 119 15.2 ELEKTA 120 15.2.1 COMPANY SNAPSHOT 120 15.2.2 REVENUE ANALYSIS 120 15.2.3 COMPANY SHARE ANALYSIS 121 15.2.4 PRODUCT PORTFOLIO 121 15.2.5 RECENT DEVELOPMENTS 121 15.3 GENERAL ELECTRIC COMPANY 122 15.3.1 COMPANY SNAPSHOT 122 15.3.2 REVENUE ANALYSIS 122 15.3.3 COMPANY SHARE ANALYSIS 123 15.3.4 PRODUCT PORTFOLIO 123 15.3.5 RECENT DEVELOPMENT 123 15.4 HITACHI, LTD. 124 15.4.1 COMPANY SNAPSHOT 124 15.4.2 REVENUE ANALYSIS 124 15.4.3 PRODUCT PORTFOLIO 125 15.4.4 RECENT DEVELOPMENT 125 15.5 KONINKLIJKE PHILIPS N.V. 126 15.5.1 COMPANY SNAPSHOT 126 15.5.2 REVENUE ANALYSIS 126 15.5.3 COMPANY SHARE ANALYSIS 127 15.5.4 PRODUCT PORTFOLIO 127 15.5.5 RECENT DEVELOPMENT 127 15.6 ACCURACY INCORPORATED 128 15.6.1 COMPANY SNAPSHOT 128 15.6.2 REVENUE ANALYSIS 128 15.6.3 PRODUCT PORTFOLIO 129 15.6.4 RECENT DEVELOPMENT 129 15.7 BEBIG MEDICAL. 130 15.7.1 COMPANY SNAPSHOT 130 15.7.2 PRODUCT PORTFOLIO 130 15.7.3 RECENT DEVELOPMENT 130 15.8 BRAINLAB AG 131 15.8.1 COMPANY SNAPSHOT 131 15.8.2 PRODUCT PORTFOLIO 131 15.8.3 RECENT DEVELOPMENTS 131 15.9 CANON MEDICAL SYSTEMS CORPORATION 132 15.9.1 COMPANY SNAPSHOT 132 15.9.2 REVENUE ANALYSIS 132 15.9.3 PRODUCT PORTFOLIO 133 15.9.4 RECENT DEVELOPMENT 133 15.10 ECKERT & ZIEGLER BEBIG 134 15.10.1 COMPANY SNAPSHOT 134 15.10.2 REVENUE ANALYSIS 134 15.10.3 PRODUCT PORTFOLIO 135 15.10.4 RECENT DEVELOPMENT 135 15.11 IBA WORLDWIDE 136 15.11.1 COMPANY SNAPSHOT 136 15.11.2 REVENUE ANALYSIS 136 15.11.3 PRODUCT PORTFOLIO 137 15.11.4 RECENT DEVELOPMENT 137 15.12 LINATECH INC 138 15.12.1 COMPANY SNAPSHOT 138 15.12.2 PRODUCT PORTFOLIO 138 15.12.3 RECENT DEVELOPMENT 138 15.13 MEVION MEDICAL SYSTEMS 139 15.13.1 COMPANY SNAPSHOT 139 15.13.2 PRODUCT PORTFOLIO 139 15.13.3 RECENT DEVELOPMENT 139 15.14 NORDION (CANADA) INC. (A SUBSIDIARY OF SOTERA HEALTH) 140 15.14.1 COMPANY SNAPSHOT 140 15.14.2 PRODUCT PORTFOLIO 140 15.14.3 RECENT DEVELOPMENT 140 15.15 P-CURE 141 15.15.1 COMPANY SNAPSHOT 141 15.15.2 PRODUCT PORTFOLIO 141 15.15.3 RECENT DEVELOPMENT 141 15.16 SHINVA MEDICAL INSTRUMENT CO., LTD. 142 15.16.1 COMPANY SNAPSHOT 142 15.16.2 PRODUCT PORTFOLIO 142 15.16.3 RECENT DEVELOPMENT 142 15.17 UNITED IMAGING HEALTHCARE CO., LTD 143 15.17.1 COMPANY SNAPSHOT 143 15.17.2 PRODUCT PORTFOLIO 143 15.17.3 RECENT DEVELOPMENT 143 15.18 VIEWRAY TECHNOLOGIES, INC. (“VIEWRAY”) 144 15.18.1 COMPANY SNAPSHOT 144 15.18.2 REVENUE ANALYSIS 144 15.18.3 PRODUCT PORTFOLIO 145 15.18.4 RECENT DEVELOPMENT 145 15.19 ZEISS INTERNATIONAL 146 15.19.1 COMPANY SNAPSHOT 146 15.19.2 REVENUE ANALYSIS 146 15.19.3 COMPANY SHARE ANALYSIS 147 15.19.4 PRODUCT PORTFOLIO 147 15.19.5 RECENT DEVELOPMENT 147 16 QUESTIONNAIRE 148 17 RELATED REPORTS 152
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(医療機器)の最新刊レポート
Data Bridge Market Research社の医療デバイス分野での最新刊レポート
本レポートと同じKEY WORD(industry)の最新刊レポート
よくあるご質問Data Bridge Market Research社はどのような調査会社ですか?データブリッジマーケットリサーチ(Data Bridge Market Research)は500名以上の多様な分野のアナリストが所属するインドの調査会社です。 もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/12/18 10:27 154.74 円 162.88 円 199.42 円 |